U.S. Markets open in 5 hrs 18 mins

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.84-0.02 (-0.07%)
At close: 4:00PM EST
Sign in to post a message.
  • B
    Biogemfinder
    Since we are talking about our “other” biotech stocks, I wanted to say that I bought a bunch of Morphosys stock $MOR or ADR just before approval. Amazingly enough the pups hasn’t jumped as much as I thought it would. The approved drug targets the same antigen CD19 like the one targeted by Amgen’s blincyto and Kites CAR-T. It was approved on fast track basis because of stellar results in DLBCL and from what I see it’s working as well as the CarT except that it’s going to be much easier to administer and going to be 5 to 10 times cheaper . Imagine that. It is going to be a real threat to CD 19 Car T and will be expanded to pretty much all B cell malignancies. Further it will move to 1st line setting in the next few years. So it’s truly a hidden gem, I have doubled up my position but I have no doubt it will be huge.
  • B
    Biogemfinder
    If anyone was on the sidelines waiting to get in Morphosys, this is the time. I doubled my position today taking advantage of this unjustified sell off $EXEL $MOR
  • M
    Martin
    $CYDY conversation
    My several thoughts about $HGEN and recently announced participation in the BET trial ("big effect trial") funded by NIAID.
    1) Lenzilumab selection was based on the compassionate use data, not on the data from the ongoing ph3 trial. This might implicate that probably no interim report data from the ongoing ph3 trial is available, which in turn might implicate that HGEN has problems with fast patients enrolment (similarly to CYDY).
    2) It is strange why now a new ph3 trial is started (with 100 patients in each arm) when another ph3 trial (with 300 patients) is already running (started already in May). The novelty regarding this new trial is that a combination of remdesivir+lenzilumab is tested as well.
    3) Actually I do not understand why this BET trial with lenzilumab (and not only with lenzilumab) has not started several months ago as soon as promising data from compassionate use has been available. At the same time (around April-May) several other arms of such trial could have been added, including leronlimab from $CYDY (targeting CCR5) or other monoclonal antibodies targeting the same cytokine (GM-CSF) as lenzilumab - i.e. mavrilimumab from $KNSA, otilimab from $MOR / $GSK, and gimsilumab from Roivant.
    4) Of course it is a good news for HGEN that NIH is interested in lenzilumab and a bad news for CYDY if leronlimab has not been considered (but this might change). But anyway, if the data from the current leronlimab trials is positive (especially in case that the S/C trial is halted by the ethical committee), there is surely no need to start a new, NIAID funded trial.
  • S
    ScottR
    Bizarre......all the great news and a billion dollars coming in and nothing on the message boards
  • a
    art
    Earf very interesting information! Looks likes lots of opportunity ! Why is this stock so lightly followed and traded? Any thoughts?
  • B
    Biogemfinder
    I just doubled my position on Morphosys $MOR It has PDFUA date in August. Approval can happen earlier. Has the potential to cross $50 in short order upon approval. $EXEL $XBI $IBB $GILD $XNCR $PFE $MRK $RHHB $PFE $BMY
  • L
    Laura
    Interesting that this stock is going up and XNCR, which will get substantial royalties on Tafasitumab, is down. Tafasitumab PDUFA as 2nd line treatment to Rituxan is coming up, and Tafasitumab is likely to eventually have broader uses than just that. It may end up being used in conjunction with Rituxan or may prove to be more effective than Rituxan. Either way, it will be at least a $2b per year drug. Any thoughts on whether it is better to invest in Tafasitumab via MOR or XNCR? I'm thinking XNCR is the better way to go.
  • a
    art
    I really do not get downward movement! Partnering with other companies spreads the risk! MOR has numerous coals in the fire! This deal should be one of many I hope down the road!
  • B
    Biogemfinder
    It's time to load up on $MOR .It appears that FDA is approving drugs (BLA. NDA) at record pace and time. The scheduled #PDFUA date for MOR202 is August 30, but be prepared to hear approval or (otherwise) sooner than that say by end of June. For some reason, the SP has been languishing in the 20s, but I beleivie its time to start accumulating. In addition, MOR also has other things in the pipeline. $XBI $IBB $QQQ $BMY $RHHB $SPY My plan is to accumulate MOR in the next 2 months which I started adding today.
  • P
    PK
    Does this Stock Trade?

    o.

    .
  • R
    Ron
    Based on their vast experience in the global healthcare and biopharmaceutical industry, in particularly in the United States, $MOR 's new Supervisory Board members will be a great support to the company in the future http://crweworld.com/article/news-provided-by-accesswire/302172/annual-general-meeting-of-morphosys-ag-elects-new-supervisory-board-members
  • a
    art
    ScottR I saw your post! Is the problem very few people know about this company in America?
  • Y
    Yahoo Finance Insights
    MOR is down 13.46% to 20.00
  • a
    art
    G was does the stock trade so poorly! Low volume and price action down? Any thoughts you might share are appreciated!
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time Low at $22.12
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time Low at $24.60
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time Low at $23.18
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time Low at $22.86
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time Low at $23.71
  • Y
    Yahoo Finance Insights
    MOR reached a new All Time High at 35.10